JNK inhibitors: is there a future?


Submitted: 20 December 2015
Accepted: 21 December 2015
Published: 28 December 2015
Abstract Views: 5377
PDF: 2056
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Jonas Cicenas MAP Kinase Resource and Institute of Animal Pathology, Bern, Switzerland; Vetsuisse Faculty, University of Bern and Proteomics Centre, Bern, Switzerland; Institute of Biochemistry, Vilnius University, Lithuania.
JNK is a subfamily of MAP kinases that hat regulates a range of biological processes implicated in response to stress, such as cytokines, ultraviolet irradiation, heat shock, and osmotic shock as well as growth factors like PDGF, EGF, FGF, etc. They were originally identified as kinases that bind and phosphorylate JUN on S63 and Se73 within its transcriptional activation domain. The deregulation of these kinases is shown to be involved in human diseases, such as cancer, immune diseases and neurodegenerative disorders. The realization of the therapeutic potential of the inhibition of JNKs led to a thorough search for small-molecule inhibitors first for research purposes, but later also for therapeutic applications. Here, we discuss some of the most well-known JNK inhibitors and their use in basic research or clinical science.

Cicenas, J. (2015). JNK inhibitors: is there a future?. MAP Kinase, 4(1). https://doi.org/10.4081/mk.2015.5700

Downloads

Download data is not yet available.

Citations